Tissue distribution of factor VIII gene expression in vivo--a closer look.

Thromb Haemost

Department of Blood Coagulation, CLB, Amsterdam, The Netherlands.

Published: September 2001

Previous studies have shown that factor VIII (FVIII) is expressed by multiple tissues. However, little is known about its cellular origin or its level of expression in different organs. In the present study, we examined FVIII gene expression in different tissues on a quantitative basis. Most of the tissues, especially liver and kidney, expressed high levels of FVIII mRNA compared to their level of expression of other hemostatic proteins, including von Willebrand factor (VWF). This was unexpected since FVIII is a trace protein. In situ hybridization analysis confirmed that liver and kidney were rich in FVIII mRNA. In the liver, a clear hybridization signal was detected in cells lining the sinusoids. FVIII mRNA analysis of purified liver cells confirmed the expression of FVIII mRNA by sinusoidal endothelial cells and Kupffer cells. Low but significant levels of FVIII mRNA were also detected in the hepatocytes. VWF mRNA was not detectable in these cells. Similarly, immunohistochemical staining of liver tissue revealed that FVIII protein is primarily associated with sinusoidal cells. VWF protein was predominantly located in the endothelium of larger vessels. In the kidney, FVIII synthesis was localized to the glomeruli and to tubular epithelial cells. Taken together, these results suggest that besides hepatocytes, non-parenchymal cells (e.g. sinusoidal endothelial cells) contribute to FVIII synthesis. VWF synthesis is primarily confined to extra-hepatic tissues.

Download full-text PDF

Source

Publication Analysis

Top Keywords

fviii mrna
20
fviii
11
cells
9
factor viii
8
gene expression
8
level expression
8
liver kidney
8
levels fviii
8
sinusoidal endothelial
8
endothelial cells
8

Similar Publications

Gene editing provides a promising alternative approach that may achieve long-term FVIII expression for hemophilia A (HemA) treatment. In this study, we investigated correction of a mutant factor VIII (FVIII) gene in HemA mice. We first developed MC3-based LNPs for efficient mRNA delivery into liver sinusoidal endothelial cells (LSECs), the major site of FVIII biosynthesis.

View Article and Find Full Text PDF

[Hemophilia A in a male cat with intermittent lameness].

Tierarztl Prax Ausg K Kleintiere Heimtiere

October 2024

Klein- und Heimtierklinik, Fachbereich Veterinärmedizin, Freie Universität Berlin.

A 3-month-old domestic shorthair tomcat born on a farm was unsuccessfully treated with meloxicam for alternating lameness, fever and inappetence. On presentation, there was lameness (grade 2/4) of the right forelimb with mild swelling of the soft tissue. Rectal temperature was 39.

View Article and Find Full Text PDF

Background: Almost half of severe hemophilia A (HA) cases are caused by an intron 22 inversion (Int22Inv) mutation, which truncates the 26-exon F8 messenger RNA (mRNA) after exon 22. Another F8 transcript, F8, is initiated from within F8-intron-22. F8 mRNA consists of a short exon spliced to exons 23 to 26 and is expressed in multiple human cell types.

View Article and Find Full Text PDF

Combined deficiency of coagulation factor V (FV) and factor VIII (FVIII) is a rare bleeding disease caused by variants in either lectin mannose binding 1 (LMAN1) or multiple coagulation factor deficiency 2 (MCFD2) gene. Reducing the level of FVIII by inhibiting the LMAN1-MCFD2 complex may become a new anticoagulant approach. We aimed to find a new therapeutic option for anticoagulation by RNA interference (RNAi) targeting LMAN1 and MCFD2.

View Article and Find Full Text PDF
Article Synopsis
  • Hemophilia A (HemA) requires regular factor VIII protein infusions, but new modified mRNA therapies could reduce the need for frequent treatments and enhance safety.
  • Researchers experimented with various base modifications in mRNA, finding that -methyl pseudouridine significantly boosts translation efficiency in liver and endothelial cells.
  • The study's mΨ modified functional FVIII mRNA, delivered via a liver-targeted lipid nanoparticle, demonstrated high therapeutic efficacy in HemA mouse models, suggesting a promising approach for treating genetic liver disorders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!